Related Experiment Video

Updated: Apr 26, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

945

NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia

D Gerloff1, R Grundler2, A A Wurm1

  • 1Division of Hematology and Oncology, Leipzig University Hospital, Leipzig, Germany.

Leukemia
|August 6, 2014
PubMed

Insights

FMS-like tyrosine kinase 3 receptor internal tandem duplication (FLT3-ITD) signaling drives acute myeloid leukemia (AML) by inducing microRNA-155 (miR-155). This oncogenic miR-155 targets PU.1, promoting leukemic cell growth.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • Acute myeloid leukemia (AML) accounts for nearly 30% of all AML cases and is associated with internal tandem duplications (ITDs) in the FMS-like tyrosine kinase 3 receptor (FLT3).
  • FLT3-ITD mutations are linked to a poor prognosis in AML patients.
  • MicroRNAs (miRNAs) play a crucial role in myeloid differentiation and the development of leukemia.

Purpose of the Study:

  • To investigate the role of microRNA-155 (miR-155) in FLT3-ITD-associated AML.
  • To elucidate the regulatory network connecting FLT3-ITD signaling, miR-155, and downstream targets.

Main Methods:

  • In vitro and in vivo experiments were conducted to study miR-155 expression.
  • Investigated the regulation of miR-155 by FLT3-ITD downstream targets, including nuclear factor-κB (p65) and signal transducer and activator of transcription 5 (STAT5).
  • Assessed the effect of miR-155 on the myeloid transcription factor PU.1 and its impact on leukemic cell proliferation and apoptosis.

Main Results:

  • FLT3-ITD signaling was found to induce the expression of oncogenic miR-155.
  • miR-155 expression is regulated by p65 and STAT5, downstream targets of FLT3-ITD.
  • miR-155 directly targets the transcription factor PU.1, and its knockdown or PU.1 overexpression inhibits proliferation and induces apoptosis in FLT3-ITD-associated AML cells.

Conclusions:

  • FLT3-ITD signaling establishes a novel oncogenic network in AML by inducing miR-155 through p65 and STAT5.
  • This network leads to the targeting of PU.1 by miR-155, contributing to leukemic cell survival and proliferation.
  • Targeting this miR-155/PU.1 axis presents a potential therapeutic strategy for FLT3-ITD-mutated AML.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.4K
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

2.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80